Yang Yonghao, Lin Hongwei, Zhao Lingdi, Song Yongping, Gao Quanli
Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Immunotherapy. 2017 Jun;9(8):629-635. doi: 10.2217/imt-2016-0133.
Metastatic renal cell carcinoma (MRCC) exhibits primary resistance to both chemotherapy and radiotherapy. As an immunogenic cancer, MRCC is relatively sensitive to immunotherapy such as that with cytokines, immune checkpoint inhibitors and adoptive T-cell therapy. In addition, many targeted agents developed over the past decade exhibit greater efficacy than cytokines and have become the standard first-line therapy for MRCC. Several preclinical studies have shown that the targeted agent sorafenib possesses an immunomodulation function and may be suitable for combination with immunotherapy. Here, combinatorial therapy consisting of sorafenib and cytokine-induced killer cell immunotherapy was administered to an MRCC patient resulting in a synergistic effect without serious adverse effects. These results suggest a potential combinatorial regimen for MRCC patients.
转移性肾细胞癌（MRCC）对化疗和放疗均表现出原发性耐药。作为一种免疫原性癌症，MRCC对免疫疗法相对敏感，如细胞因子疗法、免疫检查点抑制剂疗法和过继性T细胞疗法。此外，在过去十年中研发的许多靶向药物比细胞因子具有更高的疗效，并已成为MRCC的标准一线治疗方法。多项临床前研究表明，靶向药物索拉非尼具有免疫调节功能，可能适合与免疫疗法联合使用。在此，我们对一名MRCC患者实施了索拉非尼联合细胞因子诱导的杀伤细胞免疫疗法，结果产生了协同效应且无严重不良反应。这些结果提示了一种针对MRCC患者的潜在联合治疗方案。
